. Author manuscript; available in PMC: 2025 Jan 1.

Published in final edited form as: Gynecol Oncol. 2023 Dec 12;180:118–125. doi: 10.1016/j.ygyno.2023.11.029

Table 4.

Unadjusted and adjusted racial difference in the likelihood of diagnosis at advanced stage (i.e., regional/distant stage), as opposed to localized stage, stratified by type 1 and type 2 uterine cancer

Patient Characteristic	Model 0 (unadjusted)	Model 1 (with adjustment for symptoms)	Model 3 (with adjustme nt for symptoms and other covariates^a)
	RR (95% CI)	RR (95% CI)	RR (95% CI)
Type 1 uterine cancer^b (N=9,835)
Race
White	Reference	Reference	Reference
Black	1.03 (0.85–1.26)	1.02 (0.84–1.24)	0.98 (0.801.21)
Symptoms
PMB alone	-	Reference	Reference
PMB in conjunction with non-PMB symptoms	-	1.13 (1.03–1.25)^*	1.09 (0.99–1.20)
Non-PMB symptoms alone	-	1.41 (1.20–1.66)^*	1.37 (1.171.61)^*
No symptoms	-	0.89 (0.64–1.23)	0.90 (0.65–1.25)
Type 2 uterine cancer^b (N=7,245)
Race
White	Reference	Reference	Reference
Black	1.15 (1.10–1.22)^*	1.14 (1.08–1.20)^*	1.12 (1.061.19)^*
Symptoms
PMB alone	-	Reference	Reference
PMB in conjunction with non-PMB symptoms	-	1.11 (1.05–1.17)^*	1.09 (1.03–1.15)^*
Non-PMB symptoms alone	-	1.53 (1.43–1.62)^*	1.50 (1.401.59)^*
No symptoms	-	1.13 (0.98–1.30)^*	1.14 (0.991.31)

CI = confidence interval; PMB = postmenopausal bleeding; RR = relative risk.

indicate results with p<0.05.

^a.

Other covariates included patient age, marital status, Charlson comorbidities, socioeconomic status indicator (quintiles), Surveillance, Epidemiology and End Results (SEER) region, metropolitan/urban/rural location, and year of diagnosis.

^b.

Type 1 uterine cancer included well differentiated and moderately differentiated endometrioid carcinoma. Type 2 uterine cancer included non-endometrioid carcinoma, sarcoma, and poorly differentiated endometrioid carcinoma.